Work

Safety of veliparib in combination with chemotherapy and as maintenance in front-line ovarian cancer: Results in BRCAm, hrd, and whole populations from the velia trial

Year: 2020

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.06.040

Authors: E.M. Swisher, R.L. Coleman, M.A. Bookman, M.F. Brady, G.F. Fleming, M. Friedlander, M.J. Cunningham, K.S. Tewari, B. Edraki, K. Moxley, G.M. Mantia-Smaldone, C. Ratajczak, M.H. Dinh, D.M. Sullivan, S. McClain, S. Okubo, K.D. Steffensen, C. Aghajanian

Institutions: University of Washington Medical Center, The University of Texas MD Anderson Cancer Center, Kaiser Permanente Northern California, Roswell Park Comprehensive Cancer Center, NRG Oncology, University of Chicago, UNSW Sydney, Prince of Wales Hospital, SUNY Upstate Medical University, University of California, Irvine Medical Center, John Muir Medical Center, University of Oklahoma, Fox Chase Cancer Center, AbbVie (United States), AbbVie (Japan), Lillebaelt Hospital, Memorial Sloan Kettering Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4249408908

FWCI:

Cites:

Cited by:

Related to: 10